– USA, CA – Ciclofilin Pharmaceuticals Inc., a developer of broad spectrum antiviral medications, announced today the appointment of Michael Kamdar as a new member of the Company’s Board of Directors.

Mr. Kamdar has more than 25 years of fundraising, management, business development and commercial experience in the biotechnology, pharmaceutical and diagnostic industries. He has held a variety of executive positions at some of the most successful public and private life sciences companies, including Agouron Pharmaceuticals, Warner-Lambert, Pfizer, Anadys Pharmaceuticals, VentiRx Pharmaceuticals and Genoa Pharmaceuticals. Over the course of his career to date, Mr. Kamdar has played a key role in deal transactions valued in excess of $1 billion and has raised more than $300 million from venture capital and public capital market investors. Mr. Kamdar serves as an advisor to Microdermis and as a Director of Genoa Pharmaceuticals and BIOCOM.

Cosme Ordonez, MD, PhD, President of Ciclofilin, stated, “It is a great pleasure to welcome Michael to our Board of Directors. He brings valuable experience, skills, and industry insights gained through an outstanding career in the life sciences industry. Given his vast experience in the field of antivirals, in particular, Michael will be instrumental in helping our Company to achieve its goals on the financial, strategic and drug development fronts.”

Mr. Kamdar said, “Ciclofilin has the potential to develop a novel broad spectrum treatment for patients with viral diseases, especially those co-infected with multiple viruses. I look forward to helping the Company advance its antiviral programs to tackle this significant unmet medical need.”

About Ciclofilin Pharmaceuticals Inc.

Ciclofilin is a life sciences company based in San Diego, California, with R&D facilities in Edmonton, Canada. The company’s drug pipeline is uniquely designed to specifically target the host by rendering host cells resistant to viral infection. Unlike most other antivirals used in practice or in development, Ciclofilin’s antivirals do not target the virus. By targeting the host and not the virus, Ciclofilin’s lead drug is less susceptible to emerging resistance and is truly pangenotypic. Ciclofilin is developing a broad spectrum antiviral for the treatment of patients co-infected with hepatitis C (“HCV”), hepatitis B (“HBV”) and HIV-1 viruses. Approximately 25% of HIV patients are co-infected with HCV. Co-infected patients progress at a faster rate to end-stage liver disease than mono-infected patients, and co-infection more than triples the risk of liver disease, liver failure, and liver-related death from HCV. End-stage liver disease (liver inflammation and fibrosis, liver cirrhosis, and hepatocellular carcinoma) is the main cause of death and hospitalization for HIV patients, and cyclophilin inhibitors, as a class, are known to exhibit antifibrotic properties, which may further amplify the benefits of this approach to treating viral infections. Ciclofilin is also testing for additional antiviral indications, including human papilloma virus (“HPV”), coronaviruses and others.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

Comments are closed.